Real-World Evidence Demonstrates Significant Clinical Benefits of Abbott's FreeStyle Libre Flash Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Mar 02, 2020 11:48
CST Updated
11:48
Abbott
Diagnostic and pharmaceutical product manufacturers
- DiabetesData from the Advanced Technologies & Treatments for Diabetes (ATTD) Congress further consolidate and enrich clinical research and real-world evidence on global users of the FreeStyle Libre system.
Recently, at the 13thDiabetesDuring the Advanced Technologies & Treatments for Diabetes (ATTD) Conference,AbbottThe Company Announced Four Real-World Data Abstracts1-4. These latest data indicate that the FreeStyle Libre system can improve users' glucose control.3, increase time in glucose target range 3, reduce the occurrence of hyperglycemia4and hypoglycemia4time, and can reduce HbA1c by 1-2% (average glucose level within 3 months)2。
Mahmood Kazemi, M.D., Vice President of Global Medical and Scientific Affairs at Abbott and Chief Medical Officer of the Diabetes Care business, stated: “As the world’s leading sensor-based glucose monitoring technology, the Abbott FreeStyle Libre system has more than 2 million users. This extensive real-world evidence validates and demonstrates the clinical benefits delivered by the FreeStyle Libre system. We have repeatedly seen meaningful data confirm the direct impact of our technology on improving health outcomes for people with diabetes, and the findings presented at the Advanced Technologies & Treatments for Diabetes conference further highlight our ongoing efforts to transform lives.”
The following abstract was presented at the Advanced Technologies and Therapies in Diabetes Conference:
Using FreeStyle Libre helps improve HbA1c control in patients with type 1 or type 2 diabetes.
- HbA1c Levels Continuously Declined Over 12 Months in German Patients with Type 1 or Type 2 Diabetes on Insulin Therapy Using the FreeStyle Libre System2, which indicates that HbA1c levels in users of the Abbott FreeStyle Libre system improved and were maintained for a considerable period. The American Diabetes Association recommends that the HbA1c target for adult patients with diabetes should be below 7%.5. In patients with type 1 diabetes and baseline HbA1c greater than 7.5%, the use of the FreeStyle Libre system resulted in a mean HbA1c reduction of 1.4%, while patients with type 2 diabetes experienced a mean reduction of 1.2%. A landmark study demonstrated that an approximately 1% reduction in HbA1c levels was associated with a substantial 30% decrease in long-term diabetic complications.6。
A Real-World Study on the FreeStyle Libre System in Adult Patients with Type 1 and Type 2 Diabetes Registered in the Swedish National Diabetes Register
- Based on Important Data from the Swedish National Diabetes Register1It can be concluded that HbA1c levels significantly decreased in patients with type 1 and type 2 diabetes after using the FreeStyle Libre system for 3 to 9 months. Among first-time users of the FreeStyle Libre system, HbA1c levels decreased by 0.44% in patients with type 1 diabetes and by 0.67% in patients with type 2 diabetes.
Real-World Data Analysis on the Impact of FreeStyle Libre on Glycemic Control in Canada
- Extended Analysis of Real-World Data from Canada3, found that increasing the scanning frequency was associated with an increase in time in range (TIR), defined as the number of hours per day when glucose levels were within 70–180 mg/dL7) is associated with prolonged time in range and reduced hypoglycemia. A longer time in range indicates more stable glucose control, thereby reducing complications. Users with the lowest scanning frequency (3.3 scans per day) spent 54.6% of their time in the target range, whereas users with the highest scanning frequency (29.3 scans per day) spent 66.7% of their time in the target range.
- This analysis, together with the results of previous real-world studies8, all indicating that users with higher scanning frequencies achieved better overall glycemic control.
In the United States, the use of continuous glucose monitoring (CGM) is associated with a reduction in acute diabetes complications, even among patients who previously rarely used test strips.
- Among patients with diabetes using dynamic glucose monitoring (including the FreeStyle Libre system) for the first time, acute diabetic complications were significantly reduced in more than 12,000 individuals.4—This is also true for patients who previously performed self-monitoring of blood glucose (SMBG) using fewer than 4 test strips per day.9. A 44% significant reduction in acute diabetic complications was observed in patients with type 1 diabetes after using continuous glucose monitoring4. In patients with type 2 diabetes, a significant reduction of 51% was observed4。
Now, more than 2 million diabetes patients in 46 countries and regions have started using the Abbott FreeStyle Libre system.10Patients in 36 countries and regions can receive partial or full reimbursement when using the FreeStyle Libre system, including France, Ireland, Japan, the United Kingdom, and the United States. (Bioon.com)
References:
1. Real-world study of FreeStyle Libre system among adults with Type 1 and Type 2 diabetes within the Swedish National Diabetes Register； Katarina Eeg-Olofsson， Ann-Marie Svensson， Stefan Franzén， Hodan Ahmed Ismail， Michael T？rnblom， Fleur Levrat-Guillen
2. Improving HbA1c control in people with Type 1 or Type 2 diabetes using flash glucose monitoring： a retrospective observational analysis in two German centers； Gerhard Klausmann， Ludger Rose， Alexander Seibold
3. Canadian real-world analysis of flash glucose monitoring and glycemic control； Lori Berard，Laura Brandner
4. Acute diabetes complications defined by hypoglycemia， hypoglycemic coma， hyperglycemia， ketoacidosis， or hyperosmolarity ICD-10 codes as primary diagnosis for inpatient or as any position in the outpatient emergency claim； Matthew Kerr， Gregory Roberts， Diana Souto， Yelena Nabutovsky
5. American Diabetes Association（ADA），https：//www.diabetes.org/a1c
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus， The New England Journal of Medicine， September 30， 1993， Volume 329， Number 14
7. ADA， International Consensus on Time-In-Range. The group recommends a target range of 70-180 mg/dL [3.9-10.0 mmol/L] for individuals with Type 1 diabetes and Type 2 diabetes， and 63-140 mg/dL [3.5-7.8 mmol/L] during pregnancy， along with a set of targets for the time per day
8. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control. Presented at the 12th Advanced Technologies & Treatments for Diabetes (ATTD) in Berlin， Germany； Lang， SR Jangam
9. Compared outcomes before and after purchase of continuous glucose monitoring
10. Data on file， Abbott Diabetes Care